Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL) Meeting Abstract
| Authors: | Sznol, M.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Atkins, M. B.; Kirkwood, J. M.; Burke, M. M.; Ralabate, A. L.; Rivera, A. L.; Kronenberg, S. A.; Agunwamba, B.; Feely, W.; Hong, Q.; Krishnan, S.; Gupta, A. K.; Wolchok, J. D. |
| Abstract Title: | Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL) |
| Meeting Title: | 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 32 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2014 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2014-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358613201965 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2014.32.15_suppl.LBA9003 |
| Notes: | Meeting Abstract: LBA9003^ -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
